breast cancer
Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data
July 31, 2019Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma
Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …
MSD’s Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer
July 30, 2019Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma
MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined …
NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer
July 17, 2019Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma
Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …
Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation
July 11, 2019Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma
Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …
Roche’s Tecentriq scores CHMP recommendation in PD-L1+ metastatic triple-negative breast cancer
July 2, 2019Manufacturing and Production, Research and Development, Sales and Marketing Roche, breast cancer, pharma, tecentriq
Roche’s immunotherapy Tecentriq (atezolizumab) has been recommended by the EMA’s Committee for Medicinal Products for Human Use (CHMP) in combination …
Pfizer’s Talzenna approved in Europe for HER2- advanced breast cancer with gBRCA1/2 mutations
June 24, 2019Sales and Marketing Pfizer, breast cancer, oncology, pharma
Pfizer’s oral poly (ADP-ribose) polymerase (PARP) inhibitor Talzenna (talazoparib) has secured approval in Europe from the European Commission, the drugmaker …
Novartis’ Kisqali combo boosts survival in HR+/HER2- advanced breast cancer
June 3, 2019Research and Development, Sales and Marketing Cancer, Kisqali, Novartis, breast cancer, pharma
Novartis took the opportunity at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting to reveal new Phase 3 …
FDA approves first therapy PIK3CA-mutated HR+/HER2- advanced breast cancer
May 28, 2019Manufacturing and Production, Sales and Marketing Cancer, FDA, Novartis, Piqray, breast cancer, fulvestrant, pharma
Novartis’ Piqray (alpelisib) has secured approval from the FDA in combination with AstraZeneca’s Faslodex (fulvestrant) for the treatment of hormone …
Japan’s health ministry warns of serious side effects of Lilly’s Verzenio
May 23, 2019Business Services, Medical Communications Cancer, Eli Lilly, Verzenio, breast cancer, oncology, pharma
Japan’s Health Ministry has warned that Eli Lilly’s breast cancer therapy Verzenio could have serious side effects for patient’s lungs. …
Keytruda fails to improve overall survival in advanced triple-negative breast cancer
May 21, 2019Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma, triple-negative breast cancer
MSD has made it known that its cancer immunotherapy Keytruda (pembrolizumab) failed to meet its primary endpoint in a Phase …
Europe approves Lynparza in HER2-, gBRCAm advanced breast cancer
April 10, 2019Research and Development, Sales and Marketing AstraZeneca, Cancer, MSD, breast cancer, lynparza, pharma
Lynparza (olparib), the poly ADP ribose polymerase (PARP) inhibitor developed by AstraZeneca and MSD, has been awarded marketing approval by …
FDA approves Pfizer’s Ibrance for advanced male breast cancer
April 5, 2019Medical Communications, Sales and Marketing Cancer, FDA, Pfizer, breast cancer, ibrance, male breast cancer, pharma
The FDA has chosen to expand the indications of Pfizer’s Ibrance (palbociclib), the company announced, approving the CDK4/6 inhibitor in …
NICE recommends Eli Lilly’s Verzenio in combination with Fulvestrant for breast cancer
April 2, 2019Manufacturing and Production CDF, Cancer, NICE, breast cancer, britain, oncology
Britain’s cost effectiveness body, the National Institute for Health and Care Excellence (NICE), has recommended Eli Lilly’s Verzenio (abemaciclib) in …
Roche’s Tecentriq combo shows promise in first-line triple-negative breast cancer
April 1, 2019Research and Development, Sales and Marketing Cancer, Roche, breast cancer, pharma, tecentriq
Roche has revealed new Phase 1b data on a new Tecentriq combo, showing early promise in the first-line treatment of …
Breast cancer mortality rates fall faster in Britain than elsewhere in Europe
March 19, 2019Manufacturing and Production, Research and Development Cancer, EU, Europe, France, Italy, Poland, UK, breast cancer, german, oncology
Death rates from breast cancer are falling faster in Britain than in any of the other six most populous countries …
